Primary Mitochondrial Myopathies Overview
Primary mitochondrial myopathies (PMM) are genetically defined disorders leading to defects of oxidative phosphorylation affecting predominantly, but not exclusively, skeletal muscle. Thus, secondary involvement of mitochondria, frequently observed in other neuromuscular diseases (e.g. Duchenne muscular dystrophy) is not considered PMM. Primary mitochondrial myopathies are caused by a variation (mutation) in a gene.
“Primary Mitochondrial Myopathies Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Mitochondrial Myopathies Market.
The Primary Mitochondrial Myopathies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Primary Mitochondrial Myopathies Pipeline Report:
- Companies across the globe are diligently working toward developing novel Primary Mitochondrial Myopathies treatment therapies with a considerable amount of success over the years. Primary Mitochondrial Myopathies Key players such as – Abliva AB, Mitobridge, Reneo Pharmaceuticals, Stealth BioTherapeutics, and others, are developing therapies for the Primary Mitochondrial Myopathies treatment
- Primary Mitochondrial Myopathies Emerging therapies such as – KL 1333, Bocidelpar, REN 001, Elamipretide, and others are expected to have a significant impact on the Primary Mitochondrial Myopathies market in the coming years.
- In April 2022, Stealth BioTherapeutics Inc. initiated a trial titled “A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) – NuPower Study”
- In May 2022 Stealth BioTherapeutics Corp announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) for elamipretide for the treatment Primary Mitochondrial Myopathy.
Primary Mitochondrial Myopathies Pipeline Therapeutics Assessment
- Primary Mitochondrial Myopathies Assessment by Product Type
- Primary Mitochondrial Myopathies By Stage and Product Type
- Primary Mitochondrial Myopathies Assessment by Route of Administration
- Primary Mitochondrial Myopathies By Stage and Route of Administration
- Primary Mitochondrial Myopathies Assessment by Molecule Type
- Primary Mitochondrial Myopathies by Stage and Molecule Type
DelveInsight’s Primary Mitochondrial Myopathies Report covers around 3+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Emerging Primary Mitochondrial Myopathies Drugs Under Different Phases of Clinical Development Include:
- KL 1333: Abliva AB
- Bocidelpar: Mitobridge
- REN 001: Reneo Pharmaceuticals
- Elamipretide: Stealth BioTherapeutics
Primary Mitochondrial Myopathies Pipeline Analysis:
The Primary Mitochondrial Myopathies pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the Primary Mitochondrial Myopathies treatment with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Mitochondrial Myopathies Treatment.
- Primary Mitochondrial Myopathies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Primary Mitochondrial Myopathies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Mitochondrial Myopathies market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Primary Mitochondrial Myopathies product details are provided in the report. Download the Primary Mitochondrial Myopathies pipeline report to learn more about the emerging Primary Mitochondrial Myopathies therapies
Primary Mitochondrial Myopathies Pipeline Market Drivers
- Rising incidence of Primary Mitochondrial Myopathies
- Improving Healthcare Infrastructure
Primary Mitochondrial Myopathies Pipeline Market Barriers
- Limited number of drugs in the Pipeline
- Lack of approved drugs that target the specific cause of disease
Get a Free Sample PDF Report to know more about Primary Mitochondrial Myopathies Pipeline Assessment
Scope of Primary Mitochondrial Myopathies Pipeline Drug Insight
- Coverage: Global
- Key Primary Mitochondrial Myopathies Companies: Abliva AB, Mitobridge, Reneo Pharmaceuticals, Stealth BioTherapeutics, and others
- Key Primary Mitochondrial Myopathies Therapies: KL 1333, Bocidelpar, REN 001, Elamipretide, and others
- Primary Mitochondrial Myopathies Therapeutic Assessment: Primary Mitochondrial Myopathies current marketed and Primary Mitochondrial Myopathies emerging therapies
- Primary Mitochondrial Myopathies Market Dynamics: Primary Mitochondrial Myopathies market drivers and Primary Mitochondrial Myopathies market barriers
Request for Sample PDF Report for Primary Mitochondrial Myopathies Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Primary Mitochondrial Myopathies Report Introduction |
|
2 |
Primary Mitochondrial Myopathies Executive Summary |
|
3 |
Primary Mitochondrial Myopathies Overview |
|
4 |
Primary Mitochondrial Myopathies- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Primary Mitochondrial Myopathies Pipeline Therapeutics |
|
6 |
Primary Mitochondrial Myopathies Late Stage Products (Phase II/III) |
|
7 |
Primary Mitochondrial Myopathies Mid Stage Products (Phase II) |
|
8 |
Primary Mitochondrial Myopathies Early Stage Products (Phase I) |
|
9 |
Primary Mitochondrial Myopathies Preclinical Stage Products |
|
10 |
Primary Mitochondrial Myopathies Therapeutics Assessment |
|
11 |
Primary Mitochondrial Myopathies Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Primary Mitochondrial Myopathies Key Companies |
|
14 |
Primary Mitochondrial Myopathies Key Products |
|
15 |
Primary Mitochondrial Myopathies Unmet Needs |
|
16 |
Primary Mitochondrial Myopathies Market Drivers and Barriers |
|
17 |
Primary Mitochondrial Myopathies Future Perspectives and Conclusion |
|
18 |
Primary Mitochondrial Myopathies Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Download Sample PDF Report to know more about Primary Mitochondrial Myopathies drugs and therapies
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com